RxNorm 602549
rosiglitazone maleate 4 MG / glimepiride 2 MG Oral Tablet
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 602549 unique identifier include: rosiglitazone maleate 4 MG / glimepiride 2 MG Oral Tablet (6369277), glimepiride 2 MG / rosiglitazone 4 MG Oral Tablet (2381037), Glimepiride 2 mg and rosiglitazone (as rosiglitazone maleate) 4 mg oral tablet (12755913) and Product containing precisely glimepiride 2 milligram and rosiglitazone (as rosiglitazone maleate) 4 milligram/1 each conventional release oral tablet (clinical drug) (12757238).
RxNorm Atom ID: 6369277 - Prescribable Name
rosiglitazone maleate 4 MG / glimepiride 2 MG Oral Tablet
- RXCUI:
- 602549 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 6369277 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- NO - This drug IS NOT part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.
- Concept Description:
- rosiglitazone maleate 4 MG / glimepiride 2 MG Oral Tablet - Description of concept identifier
- Term Type (TTY):
- PSN - Term type in source with name and description
- Term Type Name:
- Prescribable Name - Name of term type in source
- Term Type Description:
- Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept. - Description of term type in source
- Code:
- 602549 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom ID: 2381037 - Semantic Clinical Drug
glimepiride 2 MG / rosiglitazone 4 MG Oral Tablet
- RXCUI:
- 602549 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 2381037 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- NO - This drug IS NOT part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.
- Concept Description:
- glimepiride 2 MG / rosiglitazone 4 MG Oral Tablet - Description of concept identifier
- Term Type (TTY):
- SCD - Term type in source with name and description
- Term Type Name:
- Semantic Clinical Drug - Name of term type in source
- Term Type Description:
- Ingredient + Strength + Dose Form - Description of term type in source
- Code:
- 602549 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom 2381037 Attributes
| Property | Value | Explanation |
|---|---|---|
| RXN AI | {317637} 25789 | RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value |
| RXN AI | {358499} 253198 | RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value |
| RXN AM | {317637} 25789 | RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value |
| RXN AM | {358499} 84108 | RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value |
| RXN BOSS FROM | {317637} AI | Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value |
| RXN BOSS FROM | {358499} AM | Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value |
| RXTERM FORM | Tab | The RxTerm dose form name for this drug |
RxNorm Atom ID: 12755913 - Designated preferred name
Glimepiride 2 mg and rosiglitazone (as rosiglitazone maleate) 4 mg oral tablet
- RXCUI:
- 602549 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12755913 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- NO - This drug IS NOT part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.
- Concept Description:
- Glimepiride 2 mg and rosiglitazone (as rosiglitazone maleate) 4 mg oral tablet - Description of concept identifier
- Term Type (TTY):
- PT - Term type in source with name and description
- Term Type Name:
- Designated preferred name - Name of term type in source
- Term Type Description:
- - Description of term type in source
- Code:
- 1208544001 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- SNOMEDCT_US - Concept source abbreviation
- Source Name:
- US Edition of SNOMED CT - The official name for a source
- Source Version:
- 2024_01_01 - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)
https://support.nlm.nih.gov/support/create-case/
- The source license contact information - Source Content Contact:
- National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library Of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)
https://support.nlm.nih.gov/support/create-case/
- The source content contact information - Source Short Name:
- US Edition of SNOMED CT - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom ID: 12757238 - Full form of descriptor
Product containing precisely glimepiride 2 milligram and rosiglitazone (as rosiglitazone maleate) 4 milligram/1 each conventional release oral tablet (clinical drug)
- RXCUI:
- 602549 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12757238 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- NO - This drug IS NOT part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.
- Concept Description:
- Product containing precisely glimepiride 2 milligram and rosiglitazone (as rosiglitazone maleate) 4 milligram/1 each conventional release oral tablet (clinical drug) - Description of concept identifier
- Term Type (TTY):
- FN - Term type in source with name and description
- Term Type Name:
- Full form of descriptor - Name of term type in source
- Term Type Description:
- - Description of term type in source
- Code:
- 1208544001 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- SNOMEDCT_US - Concept source abbreviation
- Source Name:
- US Edition of SNOMED CT - The official name for a source
- Source Version:
- 2024_01_01 - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)
https://support.nlm.nih.gov/support/create-case/
- The source license contact information - Source Content Contact:
- National Library Of Medicine
NLM is a Charter Member of SNOMED International on behalf of the U.S.
National Library Of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
1-888-FIND-NLM (1-888-346-3656)
https://support.nlm.nih.gov/support/create-case/
- The source content contact information - Source Short Name:
- US Edition of SNOMED CT - The short name of a source as used by the NLM Knowledge Source Server
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Glimepiride
Glimepiride is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Glimepiride lowers blood sugar by causing the pancreas to produce insulin (a natural substance that is needed to break down sugar in the body) and helping the body use insulin efficiently. This medication will only help lower blood sugar in people whose bodies produce insulin naturally. Glimepiride is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may occur if high blood sugar is not treated). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
[Learn More]
Rosiglitazone
Rosiglitazone is used along with a diet and exercise program and sometimes with one or more other medications to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Rosiglitazone is in a class of medications called thiazolidinediones. It works by increasing the body's sensitivity to insulin, a natural substance that helps control blood sugar levels. Rosiglitazone is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may occur if high blood sugar is not treated). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
[Learn More]
* Please review the disclaimer below.